- Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
22 Sep 2017
Novartis has enterned in new collaboration with The Max Foundation to support continued access to treatment at no cost for nearly 34,000 current patients with chronic myeloid leukemia (CML), gastrointestinal tumors (GIST) and other rare cancers.
- Sanofi, Alnylam’s ATTR amyloidosis study meets main goal
21 Sep 2017
Sanofi’s speciality care unit Genzyme together with an RNAi therapeutics company Alnylam Pharmaceuticals, announced Wednesday that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR amyloidosis with polyneuropathy, met its primary efficacy endpoint and all secondary endpoints.
- EC approves Novartis’s cancer drug for 2 indications
20 Sep 2017
The European Commission has approved Novartis’s Rydapt for two indications in rare cancers, in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy. The drug has also been approved for adults with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive.
- Alkermes gets good results testing Aristada for schizophrenia
19 Sep 2017
Alkermes revealed positive results from a phase 4 clinical study of its schizophrenia injectable drug Aristada. Alkermes said on Monday that switching to treatment with Aristada led to improvement in schizophrenia symptoms in patients with inadequate response or intolerance to Invega Sustenna.
- Allergy Therapeutics wins approval for PQ Grass phase II trial
18 Sep 2017
Allergy Therapeutics, a pharmaceutical group specialising in allergy vaccines, has announced that the fully-funded Phase II clinical trial investigating the dosing of PQ Grass has received clinical trial application (CTA) approval.
- EMA’s CHMP says No to Santhera’s Raxone in DMD, appeal on the way
15 Sep 2017
Santhera Pharmaceuticals said on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) gave a negative opinion for its Type II extension application for Raxone (idebenone) in Duchenne muscular dystrophy (DMD). Santhera plans to appeal the opinion and will seek a re-examination
- Nordic Star Awards was presented at the NLSDays conference
15 Sep 2017
Herantis Pharma, Targovax, Pelago get the Nordic Stars Award at the Nordic Life Sciences Days in Malmö, Sweden. Nordic Stars Awards winners have been selected annually since 2013 “in special recognition of life science companies in the Nordic region demonstrating outstanding innovation and entrepreneurial skills.”
- Novartis’s adalimumab offers alternative for patients with immunological diseases
14 Sep 2017
Sandoz, a Novartis division has reported new data on its proposed biosimilar adalimumab.
- Biocartis, Genomic Health bring together their Oncotype DX breast recurrence score test and Idylla platform
13 Sep 2017
Biocartis and Genomic Health have entered a deal to develop an IVD version of the Oncotype DX Breast Recurrence Score test on Biocartis’ Idylla platform that can be performed locally by laboratory partners and in hospitals around the world.
- GSK progresses regulatory filings for treating COPD with mepolizumabthis in 2017
12 Sep 2017
GlaxoSmithKline has published full results from the phase III studies for mepolizumab in chronic obstructive pulmonary disease (COPD). For people living with COPD, a sudden worsening of their symptoms, known as an exacerbation, causes them to struggle to breathe despite receiving the available guideline recommended treatment. For these patients, there are
My Pharmaceutical
Baxter, ASPEN about Parenteral Nutrition therapy
On Tuesday, the American Society for Parenteral and Enteral Nutrition (ASPEN), and Baxter International, a global leader in nutrition therapy, announced “SmartPN,” a comprehensive collaboration providing healthcare professionals with educational tools on the appropriate use of parenteral nutrition (PN) therapy.
- NIH: Social interaction affects cancer patients’ response to treatment
How well cancer patients fared after chemotherapy was affected by their social interaction with other patients during treatment, according to a new study by researchers at the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, and the University of Oxford in the United Kingdom.
- NIH: Experimental Zika virus vaccines restrict in utero virus transmission in mice
Two experimental vaccines can restrict Zika virus transmission from pregnant mice to their fetuses and can prevent Zika virus-induced placental damage and fetal demise, according to new findings published July 13 in Cell.
- Bone Therapeutics adds new board members
Bone Therapeutics, the Belgium-based bone cell therapy company focused on orthopaedics and bone diseases, has elected a new Chairman of the Board of Directors, while the previous chairman will continue as a Non-Executive Director.
